



Last Name

First Name

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

Date of Birth

		/			/								
M	M		D	D		Y	Y	Y	Y				

Dose Number: 1  2  3 **Authorization to Administer COVID-19 Vaccine**

I have read or had explained to me the Emergency Use Authorization for the use of the COVID-19 vaccine and understand the benefits and risks to me or my child of receiving this vaccine. I have had a chance to ask questions, which were answered to my satisfaction. I hereby release this provider, its employees and its volunteers from any liability for any results which may occur from the administration of this vaccine.

Signature of Patient/Parent/Legal Guardian/

Medical Durable Power of Attorney: \_\_\_\_\_

Date: \_\_\_\_/\_\_\_\_/\_\_\_\_

**STOP: DO NOT WRITE BELOW THIS LINE-FOR CLINIC STAFF ONLY**

COVID/VFC PIN

7	4	3	4				
---	---	---	---	--	--	--	--

Provider Type

 Public  
 Private

Clinic Name

M	V	U	-	5					
---	---	---	---	---	--	--	--	--	--

Provider Name

--	--	--	--	--	--	--	--	--	--	--	--	--	--

Manufacturer

 PFR (Pfizer)     AstraZeneca  
 Moderna         Novavax  
 Janssen

Lot Number

--	--	--	--	--	--	--	--	--	--	--	--	--	--

Dosage

 0.3 ml  
 0.5 ml

Site

 LD     LT  
 RD     RT

Date Administered

		/			/								
M	M		D	D		Y	Y	Y	Y				

Administered by:

Name \_\_\_\_\_ Title \_\_\_\_\_

**ADDITIONAL DOSE INFORMATION**

• Currently, CDC is recommending that **moderately to severely immunocompromised people** receive an additional dose. Applies to: Pfizer vaccine - age 12 and over; Moderna vaccine - ages 18 and over at this time. Effective 8/13/2021 for those who have:

- Been receiving active cancer treatment for tumors or cancers of the blood
- Received an organ transplant and are taking medicine to suppress the immune system
- Received a stem cell transplant within the last 2 years or are taking medicine to suppress the immune system
- Moderate or severe primary immunodeficiency (such as DiGeorge syndrome, Wiskott-Aldrich syndrome)
- Advanced or untreated HIV infection
- Active treatment with high-dose corticosteroids or other drugs that may suppress immune response ((i.e., ≥20mg prednisone or equivalent per day), alkylating agents, antimetabolites, transplant-related immunosuppressive drugs, cancer chemotherapeutic agents classified as severely immunosuppressive, tumor-necrosis (TNF) blockers, and other biologic agents that are immunosuppressive or immunomodulatory).

- The additional mRNA COVID-19 vaccine dose *should be the same vaccine product as the initial 2-dose mRNA COVID-19 primary vaccine series* (Pfizer-BioNTech or Moderna).
- If the mRNA COVID-19 vaccine product given for the first two doses is not available, the other mRNA COVID-19 vaccine product may be administered. A person should not receive more than three mRNA COVID-19 vaccine doses.
- Until additional data are available, the additional dose of an mRNA COVID-19 vaccine should be administered at least 28 days after completion of the initial 2-dose mRNA COVID-19 vaccine series, based on expert opinion.
- Currently there are insufficient data to support the use of an additional mRNA COVID-19 vaccine dose after a single-dose Janssen COVID-19 vaccination series in immunocompromised people. FDA and CDC are actively working to provide guidance on this issue.

**BOOSTER DOSE INFORMATION**

• Currently, CDC is recommending that the following people receive a booster dose at least 6 months after completion of Pfizer primary series. Applies to Pfizer ONLY. Effective 9/24/21 for:

- people 65 years and older and residents in long-term care settings should receive a booster shot of Pfizer-BioNTech's COVID-19 vaccine at least 6 months after their Pfizer-BioNTech primary series,
- people aged 50-64 years with underlying medical conditions should receive a booster shot of Pfizer-BioNTech's COVID-19 vaccine at least 6 months after their Pfizer-BioNTech primary series,
- people aged 18-49 years with underlying medical conditions may receive a booster shot of Pfizer-BioNTech's COVID-19 vaccine at least 6 months after their Pfizer-BioNTech primary series, based on their individual benefits and risks, and
- people aged 18-64 years who are at increased risk for COVID-19 exposure and transmission because of occupational or institutional setting may receive a booster shot of Pfizer-BioNTech's COVID-19 vaccine at least 6 months after their Pfizer-BioNTech primary series, based on their individual benefits and risks.